Accurate estimates of HIV prevalence in Europe are hampered by incomplete reporting of new HIV diagnoses. Defining the epidemiology of late presentation is even more challenging. In Europe, the most common definitions of late presentation are based on CD4 + T-cell counts, but there is little consistency among definitions. Thus, estimates of the incidence of late presentation vary widely between studies and across Europe, making comparative analysis difficult. Late presentation has been observed to be common in all demographic groups, but certain factors indicate greater risk for late presentation, including intravenous drug use, older age, foreign birth and non-White ethnicity. Standardizing the definition of late presentation will facilitate understanding, clinical research and, ultimately, effective treatment of late-presenting patients.
As recommended by the US Centers for Disease Control and Prevention, implementation of case surveillance of HIV is advocated in addition to existing AIDS surveillance programmes, in order to increase the pool of epidemiological data available [1] . HIV surveillance will enhance local, national and global efforts to prevent HIV transmission, improve allocation of resources for treatment services, and help to evaluate the impact of public health interventions [1] . Accurate reporting of new HIV cases is central to effective surveillance of the HIV/AIDS epidemic in Europe. However, surveillance systems record new HIV diagnoses, not new HIV infections, and therefore provide only an approximation of the true incidence of HIV. Moreover, accurate recording of new diagnoses is limited by the fact that reporting is frequently incomplete and inaccurate. In 2007, the European Centre for Disease Prevention and Control reported 48,892 newly diagnosed cases of HIV infection in countries in the World Health Organization European region [2] . However, this figure did not include data from Italy, Austria, Monaco or the Russian Federation and information was incomplete from many other countries [2] . This illustrates how under-diagnosis and under-reporting might cause incidence rates to vary between countries. With these caveats in mind, it has been estimated that in the European Union as a whole, 30% of HIV-infected individuals are undiagnosed [3] .
Attempting to define the epidemiology of late presentation is even more challenging. Low CD4 + T-cell counts at the start of HIV treatment are known to be a common and perennial challenge in the management of HIV in many countries around the world [4] . In Europe, the most common definitions of late presentation are based on CD4 + T-cell counts: either alone, in combination with clinical presentation or combined with time to development of AIDS following diagnosis of HIV [5] . Such definitions are based on CD4 + T-cell count thresholds ranging from 50 to 350 cells/µl, with <200 cells/µl being the most frequently used criterion. However, there has been little consistency between published studies as to which criteria are used. This variation, as well as changes in the way that definitions have been applied, makes it difficult to compare late presentation rates between countries or within countries over time. To make matters worse, these datasets are incomplete. CD4 + T-cell counts at diagnosis have only recently been included in surveillance programmes and, at present, are only reported for a subset of diagnosed individuals [2] .
It is clear, and probably not surprising, that varying definitions of late presentation result in varying estimates of its incidence. In studies of UK populations, for example, estimates of the incidence of late presentation have ranged between 15%, when late presentation is defined as presenting with <50 CD4 + T-cells/ µl [5] , and 33%, when late presentation is defined as presenting with <200 cells/µl [6] . A similar pattern -that the incidence of late presentation is found to be lower when a lower CD4 + T-cell cutoff definition is used -is found in other European studies [5] . The chosen denominator will also influence the estimate of incidence: estimates are lower when late presenters are reported as a proportion of all individuals with HIV than when the denominator is restricted to those who have developed AIDS [5] .
The current European AIDS Clinical Society guidelines do not include a formal definition of late presentation, but do recommend that any patients with a CD4 + T-cell count of <350 cells/µl should receive treatment, even if they are asymptomatic [7] . Findings from the SMART study suggest that the reduced risk for serious non-AIDS events provided by early use of antiviral therapy (ART) is likely to outweigh any increased risk of non-AIDS outcomes associated with ART use [8] . Furthermore, patients with a CD4 + T-cell count between 350 and 500 cells/µl, and a viral RNA load of >100,000 copies/ml should be considered for treatment [7] . These recommendations reflect the increasing availability of more convenient, better tolerated and effective antiretroviral therapies, and are in line with recommendations included in the guidelines from the British HIV Association [9] , the International AIDS Society [10] and the US Department of Health and Human Services [11] .
This approach is confirmed by a recent analysis of data from 18 cohort studies, in which rates of AIDS and death were higher when combination therapy was deferred until CD4 + T-cell counts were 251-350 cells/ µl compared with initiating at 351-450 cells/µl (hazard ratio 1.28, 95% confidence interval 1.04-1.57); the authors concluded that 350 cells/µl should be the minimum threshold for initiation of ART [12] . Furthermore, in two parallel analyses, initiation of therapy at a CD4 + T-cell count of <350 cells/µl was associated with a 69% increase in the risk of death compared with initiation at CD4 + T-cell counts between 350 and 500 cells/µl (P<0.001), whereas initiation of therapy at <500 cells/µl was associated with a 94% increase in the risk of death compared with initiation at ≥500 cells/µl (P<0.001) [13] . These were observational, non-randomized analyses. Prospective trials are required to confirm that earlier treatment is beneficial, but it is possible that current definitions of late presentation might not identify all patients who should receive treatment. An ongoing randomized, international, multicentre trial (START) will determine whether immediate antiretroviral treatment or deferred treatment (when CD4 + T-cell count decreases to <350 cells/µl) provides superior morbidity and mortality in treatment-naive HIV-infected patients with CD4 + T-cell counts >500 cells/µl [14] .
Late presentation: a national problem Table 1 summarizes estimates of late presentation obtained in studies of European populations published in the past decade. As a survey of late presentation, this survey has a number of limitations. Recent data are lacking for many countries and, where they are available, they might not be fully representative of the country as a whole, being limited to either specific demographic groups or observational cohorts. The estimates that are available vary markedly, from 10% in one Swiss analysis [15] to 45% in a Swedish study [16] and, as discussed, it is likely that a substantial amount of this variance is the result of the use of different definitions. With a few exceptions, definitions based on the presence of AIDS at diagnosis or on very low CD4 + T-cell counts estimate that late presentation affects 10−15% of patients in Europe, whereas definitions based on higher CD4 + T-cell counts estimate that late presentation affects 30−35% [5] . A further confounding factor is the denominator used to express the incidence of late presentation ( Comparison of data would be more straightforward if the latter approach was universally adopted. It is likely that variations in demographics, healthcare provision and healthcare policy affect the incidence of late presentation, but at present it is difficult to disentangle such effects from definition-based variation. Few countries have investigated changes in the incidence of late presentation over time, although studies from Sweden, Spain, France, the UK and Italy provide some useful data. The Swedish study mentioned above was a retrospective analysis of the national register of AIDS and HIV for patients diagnosed with HIV <3 months before AIDS diagnosis between 1996 and 2002 [16] . The proportion of patients presenting late with HIV (expressed as a proportion of individuals with AIDS) increased from just over 20% at the start of the study period to almost 60% for the most recent data. However, this increase was due to a decrease in the number of individuals with AIDS, rather than an increase in the number of late presenters [16] .
Similar trends were observed in a Spanish review of AIDS cases reported between 1994 and 2000 [17] , a French analysis of cases reported between 1996 and 2006 [18] , and a British study that included patients diagnosed between 1996 and 2002 [19] . However, in the British study, both the proportion of new cases accounted for by late-presenting patients and the absolute number of late-presenting patients increased over the study period. In addition, an Italian study at a centre in Modena examined median baseline CD4 + T-cell count at diagnosis increased over the time period covered by the study, but at least 25% of patients in each of the three groups presented with a CD4 + T-cell count <200 cells/µl, again suggesting the existence of a hard-to-reach group of patients at risk for late presentation [20] .
Late presentation: an individual problem
There are more comparative data available on the risk of late presentation among different demographic groups than on different European countries, and in different countries a number of groups have been identified as being at particularly high risk of late presentation. Although late presentation is common in all demographic groups, the groups at highest risk in any one country will vary depending on local barriers to testing or local policies regarding the offering of testing. Two studies using similar definitions of late presentation (CD4 + T-cell <200 cells/µl or AIDS; see Table 1) reported very different relationships between injecting drug use and late presentation [20, 21] . The French study reported that 38.7% of infected intravenous drug users presented late [21] , whereas the Italian study found no association between injecting drug use and late presentation [20] . This difference may well reflect differences in policies on access to testing or risk awareness among this patient group in the two countries.
Men who have sex with men (MSM) remain at highest risk for HIV infection overall, and yet they are often not the patients most likely to present late. In the UK, for example, where the incidence of late presentation (defined as a CD4 + T-cell count <200 cells/µl within 3 months of diagnosis) has been estimated at 31%, it is estimated that 42% of infected heterosexual men present late, compared with 36% of heterosexual women and only 19% of MSM (Figure 1 ) [22] . In France, one study found that 30.3% of MSM faced delayed access to care (based on AIDS or CD4 + T-cell <200 cells/µl at presentation) compared with 37.4% of heterosexual patients [21] . In one Croatian study, the gap was even more marked: between 2004 and 2006, 31% of MSM presented with a CD4 + T-cell count <200 cells/µl compared with 59% of heterosexual patients [23] . However, given that this risk group remains the most prevalent among those infected with HIV in most European countries, absolute numbers of latepresenting MSM remain high.
Multiple studies have also identified foreign birth [17, 20, 24] and non-White ethnicity [15] , particularly Black African or sub-Saharan origin [15, 19] , as risk factors for late presentation. Older age has also been associated with later presentation [15, 17, 19, 20, 24] , although the chosen measure of older age varies [17, 19, 20] . Being at low risk for HIV infection (that is, being outside classical risk groups) is in itself a risk factor for late testing [24] . Inconsistent results have been reported for gender as an influence on time of presentation: in two studies, male gender was independently associated with late HIV testing [17, 20] , whereas female gender was associated with increased risk for late presentation in another study [19] .
Of course, these demographic factors do not necessarily operate independently of one another. In France, an analysis of the effect of gender and migrant status on the risk of delayed access to care found that although 47.2% of migrant men experienced delayed access to care, only 35.4% of migrant women did so, compared with 37.1% and 29.2% of non-migrant men and women, respectively (Figure 2 ) [21] . Moreover, the prevalence of late presentation in any given risk group might reflect one or more of a number of factors and will vary between different countries. These factors include the following: local trends in the incidence of infection; the availability of screening programmes and the ease of access to these programmes; local clinician awareness of HIV and the risk of late presentation for HIV, as well as the willingness to carry out an HIV test; and an individual's perception of risk. Strategies for overcoming these risks are discussed in detail later in this supplement by Yazdanpanah et al. [25] , but should reflect local epidemiology. At present, despite some successful interventions, there is no evidence that the frequency of late presentation has substantially decreased over time.
The need for a common definition
Variance in the definition of late presentation used in different countries and different studies is a major complicating factor when attempting to study the epidemiology of late presentation [5] . A common European definition of late presentation would have many advantages. It would, for example, allow the coordinated identification of risk factors. Changes in the rates of late presentation could be effectively monitored over time and correlated with country-specific interventions and/or policies for earlier diagnosis.
All definitions have some limitations. Definitions based on clinical criteria, for example, may identify some patients who have a reasonable prognosis in the highly active antiretroviral therapy (HAART) era, whereas information on non-AIDS-related clinical events might be difficult to capture in many settings. Definitions based on low CD4 + T-cell count necessarily require the time and capability to assess CD4 + T-cell levels. Finally, definitions based on events that take place after diagnosis of HIV might be affected by the uptake of and response to treatment.
However, some patients can be easily identified as late presenters. If late presenters are considered as a subset of patients who should receive treatment, then any symptomatic patients -that is, those presenting with an AIDS-defining event -should be considered as late presenters. In addition, although we acknowledge that implementation of an effective surveillance system is far from a simple undertaking and requires Adapted with permission from [21] . IDU, injecting drug user; MSM, men who have sex with men.
practical, political and financial support on a national level, we argue that assessment of CD4 + T-cell levels at presentation and in HIV surveillance systems should be routine. We believe that two thresholds should be applied to the data collected to answer distinct clinical questions. Firstly, all patients who present with a CD4 + T-cell count of <350 cells/µl and/or an AIDS-defining condition should be understood to be late presenters and should be considered for treatment, in accordance with current guidelines [7, [9] [10] [11] . Secondly, all patients who present with a CD4 + T-cell count of <200 cells/µl should be considered as very late presenters. This definition is used in many countries and centres already, as the discussion above and Table 1 show, and is the established risk threshold for developing opportunistic infection [26] . In addition, both these definitions are in line with recent work by the HIV in Europe group, who suggest that an HIV patient presenting late for care is an individual presenting with an AIDS diagnosis or a CD4 + T-cell count <350 cells/µl, and that patients presenting with an AIDS diagnosis and a CD4 + T-cell count <200 cells/µl should be considered to have 'advanced HIV disease' [27, 28] .
We believe that the <350 cells/µl threshold for late presentation should be applied in studies and surveys to answer an urgent public health question: how many patients are potentially eligible for HAART, but do not receive it because they are diagnosed too late? Public health interventions can then be designed and tested to improve the diagnosis of these patients. In short, standardizing the definition of late presentation in this way will enable us to better identify what works, where and why.
